AU2014361859A1 - Long lasting effect of new botulinum toxin formulations - Google Patents

Long lasting effect of new botulinum toxin formulations Download PDF

Info

Publication number
AU2014361859A1
AU2014361859A1 AU2014361859A AU2014361859A AU2014361859A1 AU 2014361859 A1 AU2014361859 A1 AU 2014361859A1 AU 2014361859 A AU2014361859 A AU 2014361859A AU 2014361859 A AU2014361859 A AU 2014361859A AU 2014361859 A1 AU2014361859 A1 AU 2014361859A1
Authority
AU
Australia
Prior art keywords
botulinum toxin
animal
protein
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014361859A
Other languages
English (en)
Inventor
Hyun Ho Jung
Hyun Jee Kim
Chang Hoon Rhee
Gi Hyeok Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medy Tox Inc
Original Assignee
Medy Tox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014361859(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medy Tox Inc filed Critical Medy Tox Inc
Publication of AU2014361859A1 publication Critical patent/AU2014361859A1/en
Priority to AU2020203349A priority Critical patent/AU2020203349B2/en
Priority to AU2022231718A priority patent/AU2022231718A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014361859A 2013-12-12 2014-12-12 Long lasting effect of new botulinum toxin formulations Abandoned AU2014361859A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203349A AU2020203349B2 (en) 2013-12-12 2020-05-22 Long lasting effect of new botulinum toxin formulations
AU2022231718A AU2022231718A1 (en) 2013-12-12 2022-09-14 Long lasting effect of new botulinum toxin formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915476P 2013-12-12 2013-12-12
US61/915,476 2013-12-12
PCT/US2014/070113 WO2015089452A1 (en) 2013-12-12 2014-12-12 Long lasting effect of new botulinum toxin formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203349A Division AU2020203349B2 (en) 2013-12-12 2020-05-22 Long lasting effect of new botulinum toxin formulations

Publications (1)

Publication Number Publication Date
AU2014361859A1 true AU2014361859A1 (en) 2016-07-07

Family

ID=52118051

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014361859A Abandoned AU2014361859A1 (en) 2013-12-12 2014-12-12 Long lasting effect of new botulinum toxin formulations
AU2020203349A Active AU2020203349B2 (en) 2013-12-12 2020-05-22 Long lasting effect of new botulinum toxin formulations
AU2022231718A Abandoned AU2022231718A1 (en) 2013-12-12 2022-09-14 Long lasting effect of new botulinum toxin formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203349A Active AU2020203349B2 (en) 2013-12-12 2020-05-22 Long lasting effect of new botulinum toxin formulations
AU2022231718A Abandoned AU2022231718A1 (en) 2013-12-12 2022-09-14 Long lasting effect of new botulinum toxin formulations

Country Status (9)

Country Link
US (7) US9480731B2 (https=)
EP (2) EP3079714B1 (https=)
JP (4) JP6895751B2 (https=)
KR (4) KR102404218B1 (https=)
CN (2) CN116570567A (https=)
AU (3) AU2014361859A1 (https=)
CA (1) CA2933363C (https=)
ES (1) ES2861509T3 (https=)
WO (1) WO2015089452A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR20180093983A (ko) * 2015-12-11 2018-08-22 레반스 테라퓨틱스, 아이엔씨. 신경전달물질을 사용한 기분 및 정서의 일차적 질환을 위한 보툴리눔 톡신
BR112019004935A2 (pt) * 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
BR112019016585A2 (pt) * 2017-03-24 2020-03-31 Merz Pharma Gmbh & Co. Kgaa Uso melhorado da neurotoxina botulínica no tratamento da sialorreia
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
KR102531760B1 (ko) * 2017-11-13 2023-05-10 한동희 다기능성 생체적합실
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
US10918586B2 (en) * 2017-12-07 2021-02-16 Ps Therapy Ltd. Topical compositions and methods of use thereof
AU2019337656A1 (en) 2018-09-13 2021-05-06 Allergan, Inc. Methods for treatment of masseter muscle hypertrophy
CA3112394A1 (en) * 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions
TW202112943A (zh) 2019-05-23 2021-04-01 美商保爾特紡織品公司 複合材料及其製造方法
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
KR102404217B1 (ko) * 2020-04-08 2022-06-02 (주)메디톡스 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형
CN115397399B (zh) * 2020-04-08 2025-06-27 玫帝托克斯股份有限公司 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型
IL298399A (en) * 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
JP7450239B2 (ja) * 2020-08-05 2024-03-15 パナソニックＩｐマネジメント株式会社 脳卒中検査システム、脳卒中検査方法、及び、プログラム
KR102414997B1 (ko) * 2020-09-29 2022-06-29 주식회사 엘지생활건강 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물
WO2023085849A1 (ko) 2021-11-15 2023-05-19 (주)메디톡스 보툴리눔 독소 조성물
CN116440281A (zh) * 2022-01-07 2023-07-18 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物
CA3241558A1 (en) * 2022-01-14 2023-07-20 Eva AXEN Treatment of moderate to very severe glabellar lines and lateral canthal lines
AU2023333025A1 (en) 2022-09-02 2025-03-20 Medytox Inc. Botulinum toxin formulation having reduced resistance expression, and method related thereto
DE102025101336A1 (de) * 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
PT1086702E (pt) * 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7226605B2 (en) 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
MXPA01011542A (es) * 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
WO2003101483A1 (en) 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CA2510058C (en) * 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
PL1776137T3 (pl) * 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006096163A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) * 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8617568B2 (en) * 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
US8535276B2 (en) * 2008-06-26 2013-09-17 Bellanovus Development Company Llc Syringe-attached topical anesthetic dispenser
WO2010096134A1 (en) * 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
JP5688031B2 (ja) 2009-01-07 2015-03-25 ロバート ジョン ペトレラ， ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
WO2010136585A2 (en) 2009-05-29 2010-12-02 Galderma Research & Development Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
WO2011002179A2 (ko) * 2009-06-30 2011-01-06 (주)아모레퍼시픽 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
PH12012500549A1 (en) 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
SG181420A1 (en) * 2009-10-30 2012-07-30 Revance Therapeutics Inc Device and method for topical application of therapeutics or cosmetic compositions
CN102933200B (zh) * 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
JP5990176B2 (ja) * 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
WO2012134240A2 (ko) * 2011-03-31 2012-10-04 (주)메디톡스 보툴리눔 독소의 동결건조제제
KR20130022923A (ko) * 2011-08-26 2013-03-07 삼성전자주식회사 가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
EP3130347B1 (en) * 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
JP6152922B2 (ja) 2014-03-18 2017-06-28 日立金属株式会社 感圧センサ
US9579502B2 (en) * 2014-04-19 2017-02-28 Medtronic, Inc. Implantable medical leads, systems, and related methods for creating a high impedance within a conduction path in the presence of a magnetic field of a given strength
AU2016359234B2 (en) * 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
HUE052023T2 (hu) 2016-05-27 2021-04-28 Ipsen Biopharm Ltd Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
KR102088104B1 (ko) * 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
CA3112394A1 (en) * 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
UY38744A (es) 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves

Also Published As

Publication number Publication date
KR102404218B1 (ko) 2022-06-02
JP7439187B2 (ja) 2024-02-27
EP3845241A8 (en) 2021-08-18
EP3845241A1 (en) 2021-07-07
US20240424069A1 (en) 2024-12-26
JP6895751B2 (ja) 2021-06-30
AU2020203349B2 (en) 2022-06-16
CA2933363A1 (en) 2015-06-18
KR102809206B1 (ko) 2025-05-22
JP2020045360A (ja) 2020-03-26
JP2016540785A (ja) 2016-12-28
US12377137B2 (en) 2025-08-05
CA2933363C (en) 2024-01-23
EP3079714A1 (en) 2016-10-19
JP2024059717A (ja) 2024-05-01
US10143728B2 (en) 2018-12-04
JP2022161932A (ja) 2022-10-21
US20200397875A1 (en) 2020-12-24
KR20250074679A (ko) 2025-05-27
US20230149520A1 (en) 2023-05-18
US11590212B2 (en) 2023-02-28
KR20240005176A (ko) 2024-01-11
ES2861509T3 (es) 2021-10-06
US20150165003A1 (en) 2015-06-18
US20170042983A1 (en) 2017-02-16
EP3079714B1 (en) 2020-11-25
US9480731B2 (en) 2016-11-01
CN116570567A (zh) 2023-08-11
KR20220071292A (ko) 2022-05-31
US11596673B2 (en) 2023-03-07
JP7121458B2 (ja) 2022-08-18
US20250387460A1 (en) 2025-12-25
US20190099474A1 (en) 2019-04-04
CN106163545A (zh) 2016-11-23
WO2015089452A1 (en) 2015-06-18
AU2022231718A1 (en) 2022-10-06
US11957741B2 (en) 2024-04-16
AU2020203349A1 (en) 2020-06-11
KR20160113597A (ko) 2016-09-30

Similar Documents

Publication Publication Date Title
US12377137B2 (en) Long lasting effect of new botulinum toxin formulations
US12274739B2 (en) Pharmaceutical liquid composition of botulinum toxin with improved stability
CN100438905C (zh) 稳定的肉毒毒素液体制剂
HK1228255B (en) Long lasting effect of new botulinum toxin formulations

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted